What's the difference between
and
Enter two words to compare and contrast their definitions, origins, and synonyms to better understand how those words are related.

Synthetic vs Edratide - What's the difference?

synthetic | edratide |

As nouns the difference between synthetic and edratide

is that synthetic is a synthetic compound while edratide is a synthetic peptide that is used to treat cases of lupus.

As an adjective synthetic

is of, or relating to synthesis.

synthetic

English

Adjective

(en adjective)
  • Of, or relating to synthesis.
  • (chemistry) Produced by synthesis instead of being isolated from a natural source (but may be identical to a product so obtained).
  • * {{quote-magazine, date=2013-08-10, volume=408, issue=8848, magazine=(The Economist)
    • , title= A new prescription , passage=As the world's drug habit shows, governments are failing in their quest to monitor every London window-box and Andean hillside for banned plants. But even that Sisyphean task looks easy next to the fight against synthetic drugs. No sooner has a drug been blacklisted than chemists adjust their recipe and start churning out a subtly different one.}}
  • Artificial, not genuine.
  • (grammar) Pertaining to the joining of bound morphemes in a word. Compare analytic.

    • Derived terms

    * nucleosynthetic * syntheticism

    Noun

    (en noun)
  • A synthetic compound.
  • * {{quote-news, year=2007, date=January 14, author=Elsa Brenner, title=Art House to Get a Campus, work=New York Times citation
    • , passage=Only plastics and synthetics that cannot be recycled will end up in landfills, he said. }}

    edratide

    English

    Noun

    (-)
  • (medicine) A synthetic peptide that is used to treat cases of lupus
  • *{{quote-news, year=2009, date=July 20, author=Andrew Pollack, title=Trial for New Lupus Treatment Is Called Promising, work=New York Times citation
    • , passage=Among the companies that have had setbacks or outright failures in clinical trials are Roche and Biogen Idec with their drug Rituxan; La Jolla Pharmaceutical with Riquent; Bristol-Myers Squibb with Orencia; ZymoGenetics and Merck Serono with atacicept; Genelabs Technologies with Prestara; Teva Pharmaceutical Industries with edratide ; and Aspreva Pharmaceuticals and Roche with CellCept. }}